Drug maker Regeneron gains after upbeat Q2 results

Regeneron Pharmaceuticals

30/07/2026 12:23

** Shares of drug maker Regeneron Pharmaceuticals REGN.O rise 5% premarket to $730.26 after Q2 results beat estimates
** Q2 profit grows on higher sales of inflammatory diseases drug Dupixent and Eylea, an eye disease drug 
** Co beats profit estimates for fifth straight quarter - LSEG data
** REGN posts Q2 adj. EPS of $14.3 vs analysts' estimate of $10.3 - LSEG compiled data 
** Co's Q2 revenue grows 17% to $4.29 bln vs estimate of $3.82 bln
** As of last close, REGN shares down 9.9% YTD

 (Reporting by Utkarsh Hathi in Bengaluru)
 ((utkarshtushar.hathi@thomsonreuters.com))